BriaCell Therapeutics (BCTX) Competitors $1.04 -0.07 (-5.86%) (As of 11:58 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BCTX vs. MCRB, NBTX, IVA, IFRX, SKYE, RPTX, RENB, TELO, IMUX, and CNTXShould you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Seres Therapeutics (MCRB), Nanobiotix (NBTX), Inventiva (IVA), InflaRx (IFRX), Skye Bioscience (SKYE), Repare Therapeutics (RPTX), Renovaro (RENB), Telomir Pharmaceuticals (TELO), Immunic (IMUX), and Context Therapeutics (CNTX). These companies are all part of the "pharmaceutical preparations" industry. BriaCell Therapeutics vs. Seres Therapeutics Nanobiotix Inventiva InflaRx Skye Bioscience Repare Therapeutics Renovaro Telomir Pharmaceuticals Immunic Context Therapeutics BriaCell Therapeutics (NASDAQ:BCTX) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Do insiders and institutionals hold more shares of BCTX or MCRB? 15.4% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 21.8% of BriaCell Therapeutics shares are held by company insiders. Comparatively, 5.1% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in BCTX or MCRB? Seres Therapeutics received 520 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 72.01% of users gave Seres Therapeutics an outperform vote. CompanyUnderperformOutperformBriaCell TherapeuticsOutperform Votes10100.00% Underperform VotesNo VotesSeres TherapeuticsOutperform Votes53072.01% Underperform Votes20627.99% Is BCTX or MCRB more profitable? Company Net Margins Return on Equity Return on Assets BriaCell TherapeuticsN/A N/A -44.65% Seres Therapeutics N/A N/A -55.08% Which has more volatility & risk, BCTX or MCRB? BriaCell Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Does the media refer more to BCTX or MCRB? In the previous week, BriaCell Therapeutics had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 6 mentions for BriaCell Therapeutics and 3 mentions for Seres Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.70 beat Seres Therapeutics' score of 0.33 indicating that BriaCell Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BriaCell Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer BCTX or MCRB? BriaCell Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 1,335.41%. Seres Therapeutics has a consensus price target of $5.08, indicating a potential upside of 466.45%. Given BriaCell Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe BriaCell Therapeutics is more favorable than Seres Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BriaCell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has preferable earnings & valuation, BCTX or MCRB? BriaCell Therapeutics has higher earnings, but lower revenue than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBriaCell TherapeuticsN/AN/A-$4.79M-$1.17-0.89Seres Therapeutics$126.32M1.21-$113.72M-$0.23-3.90 SummaryBriaCell Therapeutics beats Seres Therapeutics on 9 of the 15 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get BriaCell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCTX vs. The Competition Export to ExcelMetricBriaCell TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.81M$6.73B$5.20B$8.97BDividend YieldN/A7.94%5.23%4.04%P/E Ratio-0.894.7285.7113.39Price / SalesN/A352.931,469.4286.49Price / CashN/A22.8835.2935.09Price / Book-6.975.604.914.96Net Income-$4.79M$151.32M$117.36M$224.10M7 Day Performance39.87%3.14%2.75%2.01%1 Month Performance31.53%-1.67%1.71%9.79%1 Year Performance-80.58%31.88%36.01%29.97% BriaCell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCTXBriaCell Therapeutics3.2896 of 5 stars$1.05-5.9%$15.00+1,335.4%-79.4%$37.81MN/A-0.8916Analyst ForecastNews CoverageGap DownMCRBSeres Therapeutics3.8896 of 5 stars$0.88-10.1%$5.08+476.7%-13.4%$150.49M$126.32M-3.83233NBTXNanobiotix2.8269 of 5 stars$3.15-2.5%$11.50+265.1%-46.0%$148.47M$36.22M0.00100Gap DownIVAInventiva3.2494 of 5 stars$2.69+1.5%$13.25+392.6%-38.0%$141.16M$15.62M0.00100Short Interest ↓IFRXInflaRx3.1557 of 5 stars$2.38-3.3%$8.00+236.1%+77.0%$140.14M$168,498.00-2.2860Positive NewsSKYESkye Bioscience1.8983 of 5 stars$4.49+5.4%$18.67+315.7%+147.4%$136.22MN/A0.0011Short Interest ↑News CoveragePositive NewsRPTXRepare Therapeutics3.785 of 5 stars$3.20-2.4%$10.00+212.5%-39.8%$136.04M$66.52M-1.64180Short Interest ↓Gap UpRENBRenovaro1.2475 of 5 stars$0.84+11.7%N/A-75.2%$134.10MN/A-0.7912News CoveragePositive NewsGap UpTELOTelomir PharmaceuticalsN/A$4.22+6.0%N/AN/A$124.95MN/A0.001Positive NewsGap UpHigh Trading VolumeIMUXImmunic3.4728 of 5 stars$1.36+9.3%$11.80+770.8%+16.7%$122.06MN/A0.0070Short Interest ↓Gap UpCNTXContext Therapeutics3.1584 of 5 stars$1.61+5.9%$6.80+322.4%+65.4%$120.75MN/A-1.677Short Interest ↓News CoverageGap Down Related Companies and Tools Related Companies MCRB Alternatives NBTX Alternatives IVA Alternatives IFRX Alternatives SKYE Alternatives RPTX Alternatives RENB Alternatives TELO Alternatives IMUX Alternatives CNTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCTX) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
